MKI67 and thyroid gland carcinoma: IHC with the Ki67 antibody confirmed that the in vivo proliferation of human thyroid carcinoma cells was increased by treatment with 1.4-2.8 mg/kg/day NaHS and decreased by treatment with 11.2 mg/kg/day NaHS.